DARÉ Bioscience
About DARÉ Bioscience
Daré Bioscience is a clinical-stage pharmaceutical company advancing products for women’s reproductive health. Women’s reproductive health encompasses a broad spectrum of categories, many of which have unmet needs. Daré is committed to developing a portfolio that expands options, improves outcomes, and enhances safety for women.YEAR FOUNDED:
2015
LEADERSHIP:
Founder & CEO: Sabrina Martucci Johnson
CFO & CBO: Lisa Walters-Hoffert
VP, Projects and Operations: Mark Walters
Board Member: Roger Hawley
166 articles about DARÉ Bioscience
-
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
4/11/2024
Daré Bioscience, Inc. today announced the publication of data from the postcoital test clinical study of Ovaprene in two original research articles in the journal Contraception.
-
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company UpdateConference Call and Webcast Today at 4:30 p.m. ET
3/28/2024
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.
-
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
3/21/2024
Daré Bioscience, Inc. today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.
-
Daré Bioscience Announces Grant to Support Biotherapeutic Product Development
1/17/2024
Daré Bioscience, Inc. today announced it has received a grant from the Bill & Melinda Gates Foundation (the foundation) of $750,000 to fund activities related to bacteria-based live biotherapeutic product development.
-
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure
12/26/2023
Daré Bioscience, Inc. announced it has entered into a royalty-backed financing agreement that provides Daré with $5 million at closing and up to an additional $7 million through three tranches over time at Daré’s option.
-
Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study
12/13/2023
Daré Bioscience, Inc. today announced that it received a Notice of Award of a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), a division of the National Institutes of Health (NIH).
-
Daré Bioscience Announces FDA Clearance of Investigational New Drug (IND) Application for DARE-VVA1
12/7/2023
Daré Bioscience, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for DARE-VVA1, a novel intravaginal proprietary formulation of tamoxifen being developed as a non-hormonal treatment option for moderate to severe dyspareunia, a symptom of VVA associated with menopause.
-
Daré Bioscience Announces Commencement of Phase 3 Study of Ovaprene®, an Investigational Hormone-Free Monthly Intravaginal Contraceptive
12/4/2023
Daré Bioscience, Inc. today announced commencement of the Company’s pivotal Phase 3 clinical study of Ovaprene, an investigational hormone-free monthly intravaginal contraceptive.
-
Daré Bioscience and Premier Research Extend Strategic Partnership to Accelerate the Clinical Development of Daré’s Novel Women’s Health Programs
11/20/2023
Daré Bioscience, Inc. and Premier Research International, LLC announced that the companies extended their partnership agreement under which Premier Research will continue to provide on an exclusive basis contract research organization services within the United States to support the clinical development of Daré’s reproductive health portfolio.
-
Daré Bioscience to Present at the Sexual Medicine Society of North America (SMSNA) 24th Annual Fall Scientific Meeting
11/13/2023
Daré Bioscience, Inc. today announced that an overview of the preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream.
-
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
11/9/2023
Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended September 30, 2023 and provided a company update.
-
Daré Bioscience to Participate in Three November 2023 Conferences
11/6/2023
Daré Bioscience, Inc., a leader in women’s health innovation, announced that the company’s President and CEO, Sabrina Martucci Johnson, and Medical Advisor Andrew T. Goldstein, MD, will participate in the following conferences in November 2023.
-
Daré Bioscience to Host Third Quarter 2023 Financial Results and Company Update Conference Call and Webcast on November 9, 2023
11/2/2023
Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results for the quarter ended September 30, 2023 and to provide a company update.
-
Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program
11/1/2023
Daré Bioscience, Inc., a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC, a Cambridge, MA based novel topical drug delivery company, announced additional positive findings based on further analyses of data from the exploratory Phase 2b RESPOND study that evaluated Sildenafil Cream, 3.6% in women with female sexual arousal disorder.
-
Daré Bioscience Announces Achievement of First Commercial Milestone Under License Agreement for XACIATO™ (Clindamycin Phosphate) Vaginal Gel, 2%, FDA-Approved Treatment for Bacterial Vaginosis in Females 12 Years or Older
10/16/2023
Daré Bioscience, Inc. announced the first shipment of XACIATOTM [pronounced zah-she-AH-toe] vaginal gel, 2% in connection with the first commercial sale of the product in the United States, triggering a $1.8 million milestone payment to Daré under its global license agreement with Organon.
-
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
9/21/2023
Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced it will receive a payment of approximately $4.5 million as the latest installment under a grant agreement to advance the development of Daré’s investigational contraceptive DARE-LARC1.
-
Daré Bioscience to Present at The Menopause Society 2023 Annual Meeting
9/20/2023
Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Dr. Andrew Goldstein, Daré Medical Advisor, will present at the 2023 Annual Meeting of The Menopause Society (formerly known as The North American Menopause Society, or NAMS) taking place September 27-30, 2023 at the Marriott Downtown in Philadelphia, PA.
-
Daré Bioscience to Participate in Upcoming Investor Conferences
9/6/2023
Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in the following investor conferences in September 2023.
-
Daré Bioscience Completes Previously Announced Equity Financing
9/5/2023
Daré Bioscience, Inc. today announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an institutional investor and an investor affiliated with the licensor of one of the company’s early stage product candidates.
-
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
8/10/2023
Daré Bioscience, Inc., a leader in women’s health innovation, reported financial results for the quarter ended June 30, 2023, and provided a company update.